Analysts Set Enovis Co. (NYSE:ENOV) Price Target at $65.86

Shares of Enovis Co. (NYSE:ENOV) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $65.86.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $65.00 price target on shares of Enovis in a research note on Thursday, November 7th.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its position in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. grew its stake in Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after buying an additional 300 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Enovis in the 3rd quarter worth $55,000. FMR LLC lifted its position in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after acquiring an additional 484 shares during the last quarter. Finally, Heritage Family Offices LLP acquired a new position in Enovis during the 3rd quarter worth $206,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Performance

Shares of NYSE ENOV opened at $44.09 on Monday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis has a one year low of $38.27 and a one year high of $65.03. The business’s 50-day moving average price is $45.82 and its two-hundred day moving average price is $44.48. The company has a market capitalization of $2.51 billion, a P/E ratio of -20.13 and a beta of 1.94.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.